A New Obesity Pill May Burn Fat Without Suppressing Appetite

GLP-1 medications, which have been injured, they are incredibly effective than the loss of weight loss. There may be a loss of gastrointestinal side effects and muscle mass. The drugs are also expensive in the United States in the United States in the United States. Drug companies are interested in the development of anti-obesity pills for relatively inexpensive prices to produce compared to injections and for some patients prefer pill.

“There is still a unemployed clinical need and the EOLO is where he wants to help,” said María Pía Garat’s CEO.

Eolo did not depart exactly to lose weight. The company’s researchers first tried to prepare a drug, especially something that occurred in the 2-type diabetes. However, when the mice began to test their experimental medications, only inflammation was not improved, but in a highly oil-fat diet caused a reduction in body weight. Experiments have performed up to nine months, and finally found that the mice fell on the start of the mice, even at the same time, at the same time.

In the mice, Sana also protected the mass of lean muscle. MRI scans shows that the mice treated with Sana, despite serious fat loss, there are more percentage of lean body mass for control.

“Hackensack University Medical Center, which does not participate in the study, and in the Metabolic Health Center” Caloric Surgery, Bariatric Surgery (Losing and the General Director of the Metabolic Health Center, “Head of Calorion Surgery and Metabolic Health Center,” says.

One of them was a phenfluramamin-fentermine, known as a fen-fenermine sold for weight loss in the 1990s, but was removed from the market for heart damage. “He is working on general metabolism. It grilled, they give you energy. This is a special oil cells, he says,” he said.

Of course, the EOLO work was very small and the medication should be tested in more people to better understand. At the end of this year, the company plans to judge about 100 participants who are obesity and will watch them in 12 weeks. They hope to hold this experiment in the United States. Garat thinks that Eolo’s medication can be used with GLP-1 medications to lose more weight, or with GLP-1 medications.

“Currently, when we need more tools, we need a back site. We need more mechanisms like this, but an initial medical community of obesity and obesity and a medical medicine and medical medical employee, not an initial medical worker specializing in obesity.

The current GLP-1S can reach 20 percent to lose 20 percent, and some patients may have enough for some patients, others may also need to lose more to reach a healthy weight. “New drugs” says, “Provides the opportunity to make a bigger impact.”